FBTA-05 is under clinical development by Lindis Biotech and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FBTA-05’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FBTA-05 overview

FBTA-05 is under development for the treatment of non-hodgkin lymphoma, diffuse large B cell lymphoma and chronic lymphocytic leukemia. The therapeutic candidate is a trifunctional bispecific antibody which acts by targeting CD3 and cell expressing B lymphocyte antigen CD20. It is being developed based on Triomab platform.

Lindis Biotech overview

Lindis Biotech (Lindis) is a drug developer that offers innovative immune-therapeutic drugs. The company develops innovative immunotherapeutic drug candidates for the treatment of small cell lung cancer, melanoma and other neuroectodermal cancers. It develops pipeline products which include Ektomun, melanoma, glioblastoma and other neuroectodermal cancer drug candidates. The company’s Ektomun is derived from Triomab platform that offers strong cancer cell-killing properties while offering vaccination against the patients’ own tumor cells. Its products also find application in validated tumor targets. Lindis is headquartered in Martinsried, Germany.

For a complete picture of FBTA-05’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.